Bruno Coudert

Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.

G. Giaccone, T. Ciuleanu, W. Brugger, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3

J. Pignon, C. Chouaid, E. Quoix, 2011, European Respiratory Journal.